{"id":"https://openalex.org/W7167497331","doi":"https://doi.org/10.1016/j.esmoop.2026.108247","title":"TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer","display_name":"TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer","publication_year":2026,"publication_date":"2026-07-01","ids":{"openalex":"https://openalex.org/W7167497331","doi":"https://doi.org/10.1016/j.esmoop.2026.108247","pmid":"https://pubmed.ncbi.nlm.nih.gov/42407196","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13355803"},"language":"en","primary_location":{"id":"doi:10.1016/j.esmoop.2026.108247","doi":"https://doi.org/10.1016/j.esmoop.2026.108247","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2026.108247","pdf_url":"https://www.esmoopen.com/article/S2059-7029(26)02189-7/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.esmoopen.com/article/S2059-7029(26)02189-7/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037671574","display_name":"Ilana Miriam Schlam","orcid":"https://orcid.org/0000-0003-4996-0400","observed_orcids":["https://orcid.org/0000-0003-4996-0400"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Schlam","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035150606","display_name":"Dario Trapani","orcid":"https://orcid.org/0000-0003-1672-9560","observed_orcids":["https://orcid.org/0000-0003-1672-9560"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"D. Trapani","raw_affiliation_strings":["Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057778866","display_name":"S J. Kim","orcid":"https://orcid.org/0000-0002-8342-8701","observed_orcids":["https://orcid.org/0000-0002-8342-8701"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.-E. Kim","raw_affiliation_strings":["Data Science, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Data Science, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034844578","display_name":"Hillary Heiling","orcid":"https://orcid.org/0000-0003-2654-3487","observed_orcids":["https://orcid.org/0000-0003-2654-3487"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Heiling","raw_affiliation_strings":["Data Science, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0003-2654-3487","affiliations":[{"raw_affiliation_string":"Data Science, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136670866","display_name":"M. Faggen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Faggen","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136676117","display_name":"N. Sinclair","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Sinclair","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5140104301","display_name":"P. Sanz-Altamira","orcid":"https://orcid.org/0009-0005-4028-2588","observed_orcids":["https://orcid.org/0009-0005-4028-2588"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Sanz-Altamira","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":"https://orcid.org/0009-0005-4028-2588","affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113824311","display_name":"C. Battelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088782","display_name":"New England Cancer Specialists","ror":"https://ror.org/009c3x903","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210088782"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Battelli","raw_affiliation_strings":["Medical Oncology, New England Cancer Specialists, Portland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, New England Cancer Specialists, Portland, USA","institution_ids":["https://openalex.org/I4210088782"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052747263","display_name":"Shana Berwick","orcid":"https://orcid.org/0000-0002-3522-1570","observed_orcids":["https://orcid.org/0000-0002-3522-1570"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Berwick","raw_affiliation_strings":["Medical Oncology, Beth Israel Deaconess Medical Center, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0002-3522-1570","affiliations":[{"raw_affiliation_string":"Medical Oncology, Beth Israel Deaconess Medical Center, Boston, USA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126275906","display_name":"S. Lo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802195419","display_name":"Stamford Hospital","ror":"https://ror.org/05jr4qt09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802195419"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Lo","raw_affiliation_strings":["Medical Oncology & Hematology, Stamford Health, Stamford, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology & Hematology, Stamford Health, Stamford, USA","institution_ids":["https://openalex.org/I2802195419"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018847112","display_name":"Jose Acevedo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]},{"id":"https://openalex.org/I1286490081","display_name":"Boston Medical Center","ror":"https://ror.org/010b9wj87","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1286490081"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Acevedo","raw_affiliation_strings":["Section of Hematology and Oncology, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Hematology and Oncology, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, USA","institution_ids":["https://openalex.org/I111088046","https://openalex.org/I1286490081"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126200724","display_name":"S. Sinclair","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Sinclair","raw_affiliation_strings":["Medical Oncology, Northern Light Health, Brewer, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Northern Light Health, Brewer, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026680793","display_name":"A. Malcolm","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Malcolm","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024374265","display_name":"Leticia Varella","orcid":"https://orcid.org/0000-0002-4371-8552","observed_orcids":["https://orcid.org/0000-0002-4371-8552"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Varella","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0002-4371-8552","affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013516632","display_name":"Sarah LeNoir Sammons","orcid":"https://orcid.org/0000-0003-2589-9422","observed_orcids":["https://orcid.org/0000-0003-2589-9422"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Sammons","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5123361738","display_name":"S. T. Schumer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Schumer","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010658926","display_name":"Philip Daniel Poorvu","orcid":"https://orcid.org/0000-0003-3664-5727","observed_orcids":["https://orcid.org/0000-0003-3664-5727"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P.D. Poorvu","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0003-3664-5727","affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136696940","display_name":"E. Wallace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Wallace","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075327319","display_name":"Esther Pasternak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Pasternak","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062515397","display_name":"Nabihah Tayob","orcid":"https://orcid.org/0000-0001-6088-167X","observed_orcids":["https://orcid.org/0000-0001-6088-167X"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Tayob","raw_affiliation_strings":["Harvard Medical School, Boston, USA; Data Science, Dana-Farber Cancer Institute, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0001-6088-167X","affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, USA; Data Science, Dana-Farber Cancer Institute, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S.M. Tolaney","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA"],"raw_orcid":"https://orcid.org/0000-0002-5940-8671","affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111775802","display_name":"Erica L. Mayer","orcid":"https://orcid.org/0000-0001-5430-8957","observed_orcids":["https://orcid.org/0000-0001-5430-8957"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"E.L. Mayer","raw_affiliation_strings":["Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Erica_Mayer@dfci.harvard.edu"],"raw_orcid":"https://orcid.org/0000-0001-5430-8957","affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Erica_Mayer@dfci.harvard.edu","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5111775802"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"],"apc_list":{"value":3910,"currency":"USD","value_usd":3910},"apc_paid":{"value":3910,"currency":"USD","value_usd":3910},"fwci":4.6982,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.95089193,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"11","issue":"7","first_page":"108247","last_page":"108247"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8100000023841858},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.843999981880188},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.8090000152587891},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.75},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.7860000133514404},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.722000002861023},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9869999885559082},{"id":"https://openalex.org/keywords/node-positive-breast-cancer","display_name":"node-positive breast cancer","score":0.8019999861717224},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.800000011920929}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8669000267982483},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6863999962806702},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6535999774932861},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6521999835968018},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.64410001039505},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.5953999757766724},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3278000056743622},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.30230000615119934},{"id":"https://openalex.org/C2779880527","wikidata":"https://www.wikidata.org/wiki/Q4959796","display_name":"Breast disease","level":4,"score":0.2628999948501587},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.26170000433921814},{"id":"https://openalex.org/C2776056953","wikidata":"https://www.wikidata.org/wiki/Q1182511","display_name":"De-escalation","level":2,"score":0.26159998774528503},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.25029999017715454}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000631","descriptor_name":"Aminopyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.esmoop.2026.108247","doi":"https://doi.org/10.1016/j.esmoop.2026.108247","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2026.108247","pdf_url":"https://www.esmoopen.com/article/S2059-7029(26)02189-7/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},{"id":"pmid:42407196","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42407196","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO open","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13355803","doi":null,"is_oa":true,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42407196/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1016/j.esmoop.2026.108247","doi":"https://doi.org/10.1016/j.esmoop.2026.108247","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2026.108247","pdf_url":"https://www.esmoopen.com/article/S2059-7029(26)02189-7/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320310151","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86"},{"id":"https://openalex.org/F4320312140","display_name":"Exelixis","ror":"https://ror.org/01e3jga91"},{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7167497331.pdf","grobid_xml":"https://content.openalex.org/works/W7167497331.grobid-xml"},"referenced_works_count":16,"referenced_works":["https://openalex.org/W1857624176","https://openalex.org/W2528767298","https://openalex.org/W2620993107","https://openalex.org/W2763875663","https://openalex.org/W2767600184","https://openalex.org/W2804105316","https://openalex.org/W2805575723","https://openalex.org/W3087501542","https://openalex.org/W3206169364","https://openalex.org/W4220778872","https://openalex.org/W4311018441","https://openalex.org/W4390706369","https://openalex.org/W4395661575","https://openalex.org/W4414508430","https://openalex.org/W4415280865","https://openalex.org/W4415280900"],"related_works":["https://openalex.org/W7129535428","https://openalex.org/W4415280865","https://openalex.org/W4410808859","https://openalex.org/W4399323723","https://openalex.org/W7204250997","https://openalex.org/W4399122002","https://openalex.org/W4411290036","https://openalex.org/W7205005123","https://openalex.org/W4401947422","https://openalex.org/W7201834746"],"abstract_inverted_index":{"BACKGROUND:":[0],"Adjuvant":[1],"abemaciclib":[2,50,117,161,184,221,285],"decreases":[3],"recurrence":[4],"rates":[5],"and":[6,35,55,202,237,291],"improves":[7],"overall":[8],"survival":[9],"for":[10,112,122,129,138,172],"patients":[11,53,102],"with":[12,103,290],"high-risk":[13],"early-stage":[14,104],"hormone":[15],"receptor":[16,21],"(HR)-positive/human":[17],"epidermal":[18],"growth":[19],"factor":[20],"2":[22,123,130,306],"(HER2)-negative":[23],"breast":[24,107],"cancer.":[25],"However,":[26],"toxicity,":[27],"particularly":[28],"diarrhea,":[29],"may":[30],"lead":[31],"to":[32,134,271,299],"dose":[33,47,59,222,236],"reductions":[34],"early":[36,46,277],"discontinuation.":[37],"Primary":[38],"results":[39],"of":[40,49,60,79,85,143,249,268,275,283,293,308],"the":[41,57,86,139,176,232,261,273,281,304],"TRADE":[42,91,263],"trial":[43,99],"demonstrated":[44],"that":[45,100],"escalation":[48],"can":[51],"help":[52],"reach":[54],"maintain":[56],"target":[58],"150":[61,135,192,233],"mg":[62,120,127,136,193,200,208,234],"twice":[63],"daily":[64],"(b.i.d.)":[65],"by":[66,162],"12":[67],"weeks":[68,84,164,267],"on":[69,165,256],"therapy.":[70,144,257,294,309],"In":[71],"this":[72],"article,":[73],"we":[74],"report":[75,146],"a":[76,93],"preplanned":[77],"analysis":[78],"clinical":[80],"outcomes":[81,241,302],"at":[82,118,149,185,218,265],"24":[83,150,163,186,266],"study.":[87],"PATIENTS":[88],"AND":[89],"METHODS:":[90],"is":[92],"prospective,":[94],"investigator-initiated,":[95],"single-arm,":[96],"phase":[97],"II":[98],"enrolled":[101],"node-positive":[105],"HR-positive/HER2-negative":[106],"cancer":[108],"who":[109,170,180,228],"were":[110,181,190,197,205],"candidates":[111],"adjuvant":[113,262,284],"abemaciclib.":[114],"Patients":[115],"initiated":[116],"50":[119,207],"b.i.d.":[121,128,137,209,235],"weeks,":[124,131,187],"then":[125,238],"100":[126,199],"before":[132],"escalating":[133],"planned":[140,305],"2-year":[141],"duration":[142],"We":[145],"key":[147],"endpoints":[148],"weeks.":[151],"RESULTS:":[152],"Among":[153,175,210],"89":[154,212],"evaluable":[155],"patients,":[156],"16":[157],"(18.0%)":[158],"had":[159,229],"discontinued":[160,171],"therapy,":[166],"including":[167,224],"7":[168],"(7.9%)":[169],"adverse":[173],"events.":[174],"73":[177],"participants":[178,226],"(82.0%)":[179],"still":[182],"receiving":[183,191,198,206],"47":[188],"(64.4%)":[189],"b.i.d.,":[194,201],"18":[195],"(24.7%)":[196,227],"8":[203],"(11.0%)":[204],"all":[211],"assessable":[213],"participants,":[214],"29":[215],"(32.6%)":[216],"required":[217],"least":[219],"one":[220],"reduction,":[223],"22":[225],"initially":[230],"reached":[231],"reduced.":[239],"Patient-reported":[240],"indicated":[242],"no":[243],"clinically":[244],"meaningful":[245],"change":[246],"in":[247,286],"quality":[248],"life":[250],"from":[251,260],"baseline":[252],"through":[253],"month":[254],"5":[255],"CONCLUSIONS:":[258],"Findings":[259],"study":[264],"follow-up":[269,296],"continue":[270,298],"demonstrate":[272],"utility":[274],"an":[276],"dose-escalation":[278],"strategy":[279],"during":[280],"initiation":[282],"optimizing":[287],"patient":[288],"persistence":[289],"tolerability":[292],"Longer-term":[295],"will":[297],"evaluate":[300],"treatment":[301],"over":[303],"years":[307]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-07-07T00:00:00"}